A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
The purpose of the trial is to assess the efficacy and safety of tirzepatide taken once a week to insulin glargine taken once daily in participants with type 2 diabetes and increased cardiovascular risk.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participant must have type 2 diabetes mellitus (T2DM)
Participant must be on stable treatment dose of at least 1 and no more than 3 oral antihyperglycemic drugs
Participant must have increased risk for cardiovascular events
Participant must be of stable weight
Participants Must Not:
Participant must not have type 1 diabetes mellitus (T1DM)
Participant must not have pancreatitis
Participant must not have disorders with slowed emptying of the stomach contents, or have had any stomach surgeries for the purpose of weight loss
Participant must not have acute or chronic hepatitis or symptoms of any other liver disease
Participant must not have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months
Participant must not have been taking weight loss drugs including over-the-counter medications during the last 3 months
Lilly Trial Alerts
You will complete the questionnaire on another website.YesNo